Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1091 entries
Sorted by: Best Match Show Resources per page
Sickness.

JAMA oncology

Shalev D.
PMID: 28448651
JAMA Oncol. 2017 Sep 01;3(9):1287. doi: 10.1001/jamaoncol.2017.0476.

No abstract available.

Cite
Shalev D. Sickness. JAMA Oncol. 2017;3(9):1287doi: 10.1001/jamaoncol.2017.0476.
Shalev, D. (2017). Sickness. JAMA oncology, 3(9), 1287. https://doi.org/10.1001/jamaoncol.2017.0476
Shalev, Daniel. "Sickness." JAMA oncology vol. 3,9 (2017): 1287. doi: https://doi.org/10.1001/jamaoncol.2017.0476
Shalev D. Sickness. JAMA Oncol. 2017 Sep 01;3(9):1287. doi: 10.1001/jamaoncol.2017.0476. PMID: 28448651.
Copy Download .nbib Format: NLM
Errata.

JAMA oncology

[No authors listed]
PMID: 27532671
JAMA Oncol. 2016 Oct 01;2(10):1374. doi: 10.1001/jamaoncol.2016.3582.

No abstract available.

Cite
Errata. JAMA Oncol. 2016;2(10):1374doi: 10.1001/jamaoncol.2016.3582.
(2016). Errata. JAMA oncology, 2(10), 1374. https://doi.org/10.1001/jamaoncol.2016.3582
"Errata." JAMA oncology vol. 2,10 (2016): 1374. doi: https://doi.org/10.1001/jamaoncol.2016.3582
Errata. JAMA Oncol. 2016 Oct 01;2(10):1374. doi: 10.1001/jamaoncol.2016.3582. PMID: 27532671.
Copy Download .nbib Format: NLM
Data Errors in Table.

JAMA oncology

[No authors listed]
PMID: 26659196
JAMA Oncol. 2015 Dec;1(9):1323. doi: 10.1001/jamaoncol.2015.5375.

No abstract available.

Cite
Data Errors in Table. JAMA Oncol. 2015;1(9):1323doi: 10.1001/jamaoncol.2015.5375.
(2015). Data Errors in Table. JAMA oncology, 1(9), 1323. https://doi.org/10.1001/jamaoncol.2015.5375
"Data Errors in Table." JAMA oncology vol. 1,9 (2015): 1323. doi: https://doi.org/10.1001/jamaoncol.2015.5375
Data Errors in Table. JAMA Oncol. 2015 Dec;1(9):1323. doi: 10.1001/jamaoncol.2015.5375. PMID: 26659196.
Copy Download .nbib Format: NLM
Incorrect Drug Name. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.

JAMA oncology

[No authors listed]
PMID: 26181035
JAMA Oncol. 2015 May;1(2):255. doi: 10.1001/jamaoncol.2015.1156.

No abstract available.

Cite
Incorrect Drug Name. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. JAMA Oncol. 2015;1(2):255doi: 10.1001/jamaoncol.2015.1156.
(2015). Incorrect Drug Name. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. JAMA oncology, 1(2), 255. https://doi.org/10.1001/jamaoncol.2015.1156
"Incorrect Drug Name. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015." JAMA oncology vol. 1,2 (2015): 255. doi: https://doi.org/10.1001/jamaoncol.2015.1156
Incorrect Drug Name. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. JAMA Oncol. 2015 May;1(2):255. doi: 10.1001/jamaoncol.2015.1156. PMID: 26181035.
Copy Download .nbib Format: NLM
Error in Abstract. Correlation of Smoking- Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer.

JAMA oncology

[No authors listed]
PMID: 26181275
JAMA Oncol. 2015 Jul;1(4):544. doi: 10.1001/jamaoncol.2015.2066.

No abstract available.

Cite
Error in Abstract. Correlation of Smoking- Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. JAMA Oncol. 2015;1(4):544doi: 10.1001/jamaoncol.2015.2066.
(2015). Error in Abstract. Correlation of Smoking- Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. JAMA oncology, 1(4), 544. https://doi.org/10.1001/jamaoncol.2015.2066
"Error in Abstract. Correlation of Smoking- Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer." JAMA oncology vol. 1,4 (2015): 544. doi: https://doi.org/10.1001/jamaoncol.2015.2066
Error in Abstract. Correlation of Smoking- Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. JAMA Oncol. 2015 Jul;1(4):544. doi: 10.1001/jamaoncol.2015.2066. PMID: 26181275.
Copy Download .nbib Format: NLM
Emergency Department-Initiated Palliative Care in Advanced Cancer: A Randomized Clinical Trial.

JAMA oncology

Grudzen CR, Richardson LD, Johnson PN, Hu M, Wang B, Ortiz JM, Kistler EA, Chen A, Morrison RS.
PMID: 26768772
JAMA Oncol. 2016 May 01;2(5):591-598. doi: 10.1001/jamaoncol.2015.5252.

IMPORTANCE: The delivery of palliative care is not standard of care within most emergency departments (EDs).OBJECTIVE: To compare quality of life, depression, health care utilization, and survival in ED patients with advanced cancer randomized to ED-initiated palliative care consultation...

Cite
Grudzen CR, Richardson LD, Johnson PN, et al. Emergency Department-Initiated Palliative Care in Advanced Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016;2(5):591-598doi: 10.1001/jamaoncol.2015.5252.
Grudzen, C. R., Richardson, L. D., Johnson, P. N., Hu, M., Wang, B., Ortiz, J. M., Kistler, E. A., Chen, A., & Morrison, R. S. (2016). Emergency Department-Initiated Palliative Care in Advanced Cancer: A Randomized Clinical Trial. JAMA oncology, 2(5), 591-598. https://doi.org/10.1001/jamaoncol.2015.5252
Grudzen, Corita R, et al. "Emergency Department-Initiated Palliative Care in Advanced Cancer: A Randomized Clinical Trial." JAMA oncology vol. 2,5 (2016): 591-598. doi: https://doi.org/10.1001/jamaoncol.2015.5252
Grudzen CR, Richardson LD, Johnson PN, Hu M, Wang B, Ortiz JM, Kistler EA, Chen A, Morrison RS. Emergency Department-Initiated Palliative Care in Advanced Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016 May 01;2(5):591-598. doi: 10.1001/jamaoncol.2015.5252. PMID: 26768772.
Copy Download .nbib Format: NLM
Missing Middle Initial in Author's Name.

JAMA oncology

[No authors listed]
PMID: 26869004
JAMA Oncol. 2016 Feb;2(2):279. doi: 10.1001/jamaoncol.2015.6541.

No abstract available.

Cite
Missing Middle Initial in Author's Name. JAMA Oncol. 2016;2(2):279doi: 10.1001/jamaoncol.2015.6541.
(2016). Missing Middle Initial in Author's Name. JAMA oncology, 2(2), 279. https://doi.org/10.1001/jamaoncol.2015.6541
"Missing Middle Initial in Author's Name." JAMA oncology vol. 2,2 (2016): 279. doi: https://doi.org/10.1001/jamaoncol.2015.6541
Missing Middle Initial in Author's Name. JAMA Oncol. 2016 Feb;2(2):279. doi: 10.1001/jamaoncol.2015.6541. PMID: 26869004.
Copy Download .nbib Format: NLM
Error in Corresponding Author Address.

JAMA oncology

[No authors listed]
PMID: 26869005
JAMA Oncol. 2016 Feb;2(2):279. doi: 10.1001/jamaoncol.2016.0032.

No abstract available.

Cite
Error in Corresponding Author Address. JAMA Oncol. 2016;2(2):279doi: 10.1001/jamaoncol.2016.0032.
(2016). Error in Corresponding Author Address. JAMA oncology, 2(2), 279. https://doi.org/10.1001/jamaoncol.2016.0032
"Error in Corresponding Author Address." JAMA oncology vol. 2,2 (2016): 279. doi: https://doi.org/10.1001/jamaoncol.2016.0032
Error in Corresponding Author Address. JAMA Oncol. 2016 Feb;2(2):279. doi: 10.1001/jamaoncol.2016.0032. PMID: 26869005.
Copy Download .nbib Format: NLM
Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals.

JAMA oncology

Wong MCS, Wong JCT.
PMID: 28654934
JAMA Oncol. 2017 Oct 01;3(10):1426-1427. doi: 10.1001/jamaoncol.2017.1504.

No abstract available.

Cite
Wong MCS, Wong JCT. Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals. JAMA Oncol. 2017;3(10):1426-1427doi: 10.1001/jamaoncol.2017.1504.
Wong, M. C. S., & Wong, J. C. T. (2017). Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals. JAMA oncology, 3(10), 1426-1427. https://doi.org/10.1001/jamaoncol.2017.1504
Wong, Martin C S, and Wong, John C T. "Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals." JAMA oncology vol. 3,10 (2017): 1426-1427. doi: https://doi.org/10.1001/jamaoncol.2017.1504
Wong MCS, Wong JCT. Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals. JAMA Oncol. 2017 Oct 01;3(10):1426-1427. doi: 10.1001/jamaoncol.2017.1504. PMID: 28654934.
Copy Download .nbib Format: NLM
Incorrect Spelling in Byline.

JAMA oncology

[No authors listed]
PMID: 29543964
JAMA Oncol. 2018 Apr 01;4(4):590. doi: 10.1001/jamaoncol.2018.0640.

No abstract available.

Cite
Incorrect Spelling in Byline. JAMA Oncol. 2018;4(4):590doi: 10.1001/jamaoncol.2018.0640.
(2018). Incorrect Spelling in Byline. JAMA oncology, 4(4), 590. https://doi.org/10.1001/jamaoncol.2018.0640
"Incorrect Spelling in Byline." JAMA oncology vol. 4,4 (2018): 590. doi: https://doi.org/10.1001/jamaoncol.2018.0640
Incorrect Spelling in Byline. JAMA Oncol. 2018 Apr 01;4(4):590. doi: 10.1001/jamaoncol.2018.0640. PMID: 29543964; PMCID: PMC8177282.
Copy Download .nbib Format: NLM
PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer.

JAMA oncology

Pennell NA.
PMID: 26986805
JAMA Oncol. 2016 May 01;2(5):569-570. doi: 10.1001/jamaoncol.2016.0040.

No abstract available.

Cite
Pennell NA. PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer. JAMA Oncol. 2016;2(5):569-570doi: 10.1001/jamaoncol.2016.0040.
Pennell, N. A. (2016). PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer. JAMA oncology, 2(5), 569-570. https://doi.org/10.1001/jamaoncol.2016.0040
Pennell, Nathan A. "PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer." JAMA oncology vol. 2,5 (2016): 569-570. doi: https://doi.org/10.1001/jamaoncol.2016.0040
Pennell NA. PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer. JAMA Oncol. 2016 May 01;2(5):569-570. doi: 10.1001/jamaoncol.2016.0040. PMID: 26986805.
Copy Download .nbib Format: NLM
Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply.

JAMA oncology

Niravath P, Cakar B, Ellis M.
PMID: 28520826
JAMA Oncol. 2017 Sep 01;3(9):1284. doi: 10.1001/jamaoncol.2017.0665.

No abstract available.

Cite
Niravath P, Cakar B, Ellis M. Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply. JAMA Oncol. 2017;3(9):1284doi: 10.1001/jamaoncol.2017.0665.
Niravath, P., Cakar, B., & Ellis, M. (2017). Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply. JAMA oncology, 3(9), 1284. https://doi.org/10.1001/jamaoncol.2017.0665
Niravath, Polly, et al. "Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply." JAMA oncology vol. 3,9 (2017): 1284. doi: https://doi.org/10.1001/jamaoncol.2017.0665
Niravath P, Cakar B, Ellis M. Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply. JAMA Oncol. 2017 Sep 01;3(9):1284. doi: 10.1001/jamaoncol.2017.0665. PMID: 28520826.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1091 entries